Eli Lilly's experimental obesity drug could be 'revolutionary,' says Jim Cramer

Eli Lilly's experimental obesity drug could be 'revolutionary,' says Jim CramerПодробнее

Eli Lilly's weight-loss drug could be the best selling drug of all time, says Jim CramerПодробнее

Jim Cramer explains why he favors Eli Lilly in the weight loss drug spaceПодробнее

Jim Cramer weighs the market impact of Eli Lilly and Novo Nordisk's weight loss drugsПодробнее

I get stories every day from patients about how Mounjaro is benefiting their lives: Eli Lilly CEOПодробнее

Eli Lilly could have the 'biggest drug in history' in its pipeline, says Jim CramerПодробнее

Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicineПодробнее

Jim Cramer on how Eli Lilly could be impacted by mixed Alzheimer's drug study resultsПодробнее

Lightning Round: The lithium group is played out, says Jim CramerПодробнее

Eli Lilly could be the next stock to cross $1 trillion, says Jim CramerПодробнее

FDA approves Eli Lilly obesity drugПодробнее

Eli Lilly CEO talks expanding innovation past obesity drugsПодробнее

Eli Lilly CEO David Ricks breaks down Q1 earnings, obesity drug trial resultsПодробнее

Eli Lilly and Novo can 'coexist for awhile' in the weight-loss drug space, says BMO's Evan SeigermanПодробнее

Obesity drug could be a 'big upside' for Eli Lilly, says Wells Fargo's Mohit BansalПодробнее

Cramer’s Mad Dash: Eli LillyПодробнее

Eli Lilly CEO David Ricks on GLP-1 and obesity drugsПодробнее

New developments in weight-loss drugs: Novo Nordisk, Eli Lilly & Pfizer advance studiesПодробнее

The apparel space could stand to benefit from the rise of weight-loss drugs, says Jim CramerПодробнее

Potential for Weight-Loss Drugs Boosts Eli LillyПодробнее